Lakewood-Amedex Biotherapeutics Inc. 8-K

What Happened

• Lakewood-Amedex Biotherapeutics (LABT) filed an 8-K reporting that the Board appointed Dr. Joseph Tucker as a director effective April 24, 2026. He will serve until the company’s 2027 annual meeting of stockholders and until a successor is elected or earlier death, resignation, or removal.
• The filing (Item 5.02) notes Dr. Tucker’s biotech leadership background (current CEO/director of Enveric Biosciences; prior CEO roles at MagicMed, VirTech Bio, Willow Biosciences, Stem Cell Therapeutics) and that the company cited his experience raising capital and executing strategic transactions as reasons for the appointment.

Key Details

• Age: 57. Educational/credentials: Ph.D. and B.Sc. (University of Calgary); Certified Financial Planner; named inventor on 13 U.S. patents.
• Compensation: $6,000 per quarter payable in shares of common stock.
• Equity award: 33,784 warrants to purchase common stock at $10.00 per share, 10-year term; vesting in four equal tranches of 8,446 warrants on 10/24/2026, 4/24/2027, 10/24/2027, and 4/24/2028. Unvested warrants are cancelled if the Company terminates the Board Agreement.
• Board duties/commitments: expected to attend up to four (minimum two) board meetings per year, be available for ad-hoc consultation, reimbursed for pre-approved travel/living expenses. Assigned to Finance/Audit & Risk, Compensation, and Corporate Governance & Nominating committees.
• Agreement terms: Board Agreement continues indefinitely unless terminated; includes confidentiality, work-product ownership, and a 12-month post-service non-solicitation covenant.

Why It Matters

• The company added an experienced public-biotech CEO and dealmaker, which may strengthen board oversight of financing, M&A, IPOs and strategic planning. His committee assignments include Finance/Audit and Risk, so he will be involved in financial oversight.
• Compensation is equity-heavy (stock payments and warrants). That aligns his interests with shareholders but could increase share count if warrants are exercised (exercise price $10.00). Investors should note the specific vesting schedule and cancellation terms disclosed in the 8-K.